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Abstract
Background Skin autofluorescence (sAF) was examined as a
marker of the accumulation of advanced glycation end
products (AGEs) in tissues of children with chronic kid-
ney disease (CKD) in relation to renal function, dialysis
modality and markers of endothelial inflammation and
dysfunction.
Methods A total of 76 children with CKDwere enrolled in the
study, of whom 20 children were on hemodialysis (HD), 20
were on peritoneal dialysis (PD) and 36 were treated conser-
vatively. A control group of 26 healthy subjects was also
included in the study. In all children, sAF intensity, carotid
intima-media (cIMT) thickness and plasma concentrations of
sE-selectin, matrix metalloproteinase 9 (MMP-9), tissue in-
hibitor of metalloproteinase 1 (TIMP-1), asymmetric
dimethylarginine (ADMA), symmetric dimethylarginine
(SDMA) and plasminogen activator inhibitor type 1 (PAI-1)
were measured.
Results Compared to the controls, children with CKD had
significantly elevated sAF levels. sAF in the children with
CKD was positively correlated with sE-selectin, MMP-9,
TIMP-1, ADMA, SDMA and PAI-1 levels. In the predialysis
group (conservative treatment) sAF levels were positively
correlated with sE-selectin and ADMA levels and negatively
correlated with glomerular filtration rate. Multiple regression
analysis showed a significant association of sAF with sE-
selectin and MMP-9 in CKD children.
Conclusions The results reveal that AGEs were accumulated
in the children with CKD. This accumulation was related to
early vascular changes and a number of biochemical vascular
risk markers. sAF measurement, as a noninvasive method,
may be useful for identification of clinical risk factors of
vascular disease in CKD children.
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Introduction
Cardiovascular complications, including atherosclerosis, are
the major cause of morbidity and mortality in patients with
chronic kidney disease (CKD) [1], especially in those on
maintenance dialysis [2].
The generation of advanced glycation end products
(AGEs) is increased in patients with CKD, which contributes
to vascular injury, irrespective of traditional risk factors, such
as hypertension, lipid and mineral disorders, smoking and
diabetes [3]. AGEs are formed and accumulate as a result of
increased oxidative and carbonyl stress and due to reduced
renal excretion of their precursors [4]. It has been shown that
the increased generation of oxygen free radicals and carbonyl
compounds in patients with CKD already occurs in the early
stages of the disease and is exacerbated along with its pro-
gression [5–7]. The accumulation of AGEs in atherosclerotic
plaques which form in the arterial wall of patients with end-
stage kidney disease (ESKD) indicates the participation of
AGEs in the development of atherosclerotic lesions [8]. The
presence of lipoproteins bound to AGEs may increase
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deposits of oxidized low-density lipoprotein (LDL)-cholester-
ol in blood vessels, which in turn is associated with the
impaired clearance of LDL by a specific receptor [9].
Recent studies have confirmed that AGEs may also play
a significant role in the pathogenesis of atherosclerosis
through their ability to induce the inflammatory reaction
via activation of the receptor for AGEs (RAGE). This
receptor is found on various cells, including monocytes,
macrophages, vascular endothelial cells and muscle
cells. Stimulation of RAGE has been found to increase
the expression of adhesion molecules and pro-inflammatory
cytokines and stimulate intimal thickening of the arteries
and activation of nuclear factor kappa-B, which results
in the activation of the inflammatory response and
causes stimulation of the host immune system [10,
11]. RAGE receptors located on the vascular endotheli-
um are a crucial factor leading to endothelial dysfunc-
tion [10]. The accumulation of AGEs in vascular tissue
has a positive correlation with cardiovascular complica-
tions and impaired diastolic heart muscle function in
adult patients [12].
It has recently become possible to non-invasively examine
the level of AGEs in tissues using the measurement of skin
autofluorescence (sAF). Ueno et al. [13] recently confirmed
the usefulness of sAF as a predictive marker of the AGE level
in tissues by demonstrating a high correlation between sAF
and specific AGEs in skin homogenate slices. In a previous
study by our research group involving children and adoles-
cents with CKD, we showed for the first time that sAF level is
significantly positively correlated with indices of cardio-
vascular system damage, such as the index of left ventricular
mass and arterial stiffness, based on the alteration in the
measurement of pulse wave velocity in the aorta [14]. Elevat-
ed values of sAF have been found in patients with acute
myocardial infarction and stable coronary artery disease and
in adult patients treated with hemodialysis [11]. A high sAF
level has been recognized as a predictive factor of increased
cardiovascular mortality in adult patients with diabetes and
ESKD [15]. Hartog et al. confirmed that increased sAF is an
independent predictor of graft function loss in patients who
have undergone kidney transplantation [16]. Some authors,
including those just mentioned, have concluded that the mea-
surement of sAF can be considered to be a reliable marker of
the intensity of inflammation, oxidative stress and atheroscle-
rosis in diseases that generate early complications of the
cardiovascular system.
The aim of the study presented here was to evaluate the role
of sAF in identifying early vascular changes leading to the
development of premature atherosclerosis in children and
adolescents with CKD at different stages of the disease. We
determined the correlations between sAF and carotid intima-
media thickness (cIMT) and the so-called new risk markers
for atherosclerosis.
Patients and methods
Patients
Seventy-six children with CKD, yet asymptomatic in terms of
cardiovascular complications, were enrolled in the study. The
patients were divided into three groups according to CKD
stage 2–4 [predialysis (Pre) group] and dialysis modality
[peritoneal dialysis (PD) and hemodialysis (HD) groups, re-
spectively]. The control group comprised 26 age-matched
children with primary nocturnal enuresis and normal kidney
function. The clinical and demographic details of the study
subjects are summarized in Table 1.
The PD group included 20 children on PD, with 12
patients on night intermittent PD and eight patients on contin-
uous cyclic PD in eight patients. For all PD patients, the
HomeChoice automated PD system was used (Baxter Inter-
national, Inc., Deerfield, IL). Standard dialysis solutions with
1.5 and 2.3 % glucose concentration and 1.25 or 1.75 mmol/l
calcium concentration were applied according to individual
recommendations. The causes of CKD in children in the PD
group included structural urinary tract abnormalities (9 pa-
tients), glomerulonephritis (5), polycystic kidney disease (3),
hereditary nephropathy (2) and hemolytic uremic syndrome
(1). Fifteen children remained on hypotensive medication,
which included angiotensin-converting enzyme inhibitors
(ACEi) (13 patients), calcium channel blockers (6) and β-
blockers (3). All patients received calcium-containing phos-
phate binders and vitamin D metabolites in doses adjusted to
current requirements.
The HD group included 20 children on maintenance HD.
Dialysis sessions were performed three times a week (3–5 h)
using polysulfone membranes.Blood flow ranged from 120 to
250 ml/min, and dialysate flow did not exceed 500 ml/min.
Dialysis fluid was buffered with bicarbonate and contained
1.25 or 1.5 mmol/l calcium. The causes of CKD in this group
were urinary tract abnormalities (CAKUT) (12 patients), glo-
merulonephritis (6) and hereditary glomerulopathy (2). Nine-
teen hypertensive children were treated with ACEi (19 pa-
tients), calcium channel blockers (11) and/or β-blockers (2)
patients. All HD patients received calcium-containing phos-
phate binders and vitamin D compounds.
The Pre group included 36 children with CKD stage 2–4 on
conservative treatment. The causes of CKD in this group were
urinary tract malformations (22 patients), glomerulonephritis
(5), polycystic kidney disease (3), hereditary glomerulopathy
(2), unknown cause(s) (2), hemolytic uremic syndrome (1)
and complications after chemotherapy for cancer (1). Stage 2
CKD was detected in 13 children, stage 3 in ten children and
stage 4 in 13 children. Twelve patients were treated with ACE-
I, six were treated with angiotensin receptor blockers, four
received calcium channel blockers and one received a
β-blocker.
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All patients with CKD stage 3 and 4, and five children with
stage 2 received treatment with calcium-containing phosphate
binders and vitamin D compounds.
Children under 6 years of age and patients with diabetes
and infection were excluded from the study. Informed consent
for participation in the study was obtained from all the parents
and children over the age of 15 years. The research project
was approved by the Wroclaw Medical University ethics
committee.
Methods
Progression of CKD was evaluated in accordance with the
KidneyDisease Outcomes Quality Initiative (K/DOQI) guide-
lines published in 2002 [17]. Estimated glomerular filtration
rate (GFR) was determined by the Schwartz formula [18]. All
children underwent the following examinations: serum creat-
inine, blood pressure measurement (BP), sAF assessment,
carotid intima-media thickness (cIMT) evaluation and body
mass index (BMI) determination. Blood samples obtained
after overnight fasting were drawn from the peripheral vein
in patients from the PD, Pre and control groups and from the
afferent line prior to starting an HD session in HD children.
Biochemical tests on serum samples included creatinine level
estimation. The parameters were measured according to auto-
mated standardized laboratory techniques in the clinical labo-
ratory using a multichannel analyzer (model KONELAB30i;
Thermo Fisher Scientific Inc., bioMérieux, Marcy l'Etoile,
France). Blood for the evaluation of endothelial markers was
collected in dry tubes and subsequently centrifuged (3,000 g,
15 min); the serum was frozen and stored at −20 °C until
assayed. Blood for plasminogen activator inhibitor-1 (PAI-1)
measurement was collected in EDTA tubes and centrifuged
(1,000 g for 15 min) within 30 min of collection. After
separation from blood cells, the plasma was frozen and stored
at −20 °C until assayed.
sE-selectin, asymmetric dimethylarginine (ADMA), sym-
metric dimethylarginine (SDMA), matrix metalloproteinase 9
(MMP-9), tissue inhibitor of metalloproteinase 1 (TIMP-1)
and PAI-1 levels, respectively, were determined twice, and the
average values were used for analysis. sE-selectin/CD62E
was assessed using a commercially available enzyme-linked
immunosorbent assay (ELISA) kit (R&D Systems, Inc. Min-
neapolis, MN) according to the manufacturer’s instructions.
Commercially available ELISA kits were also used to deter-
mine ADMA (Immundiagnostik AG, Bensheim, Germany),
TIMP-1 and PAI-1/Human Serpin E1 (ELISA kits; R&D
Systems). SDMAwas determined using a DLD Diagnostika
GmbH kit (Hamburg, Germany), and MMP-9 was deter-
mined using a kit produced by R&D Systems, Inc.
Both weight and height were measured using standardized
protocols. BMI was calculated as weight in kilograms divided
by height in meters squared.
BP measurements with the oscillometric device were per-
formed according to the recommendations of the Fourth Re-
port of the Blood Pressure Control in Children Working
Group [19].
Skin autofluorescence
Skin autofluorescence was assessed using the AGE Reader
device (Diagnoptics BV, Groningen, The Netherlands) as
described previously in detail by Meerwald et al. [20]. This
is a noninvasive device used to assess the accumulation of
fluorescent AGEs in tissues. In brief, the ratio of the average
light intensity per nanometer in the range between 420 to
600 nm emitted by the source divided by the average of
excited light intensity per nanometer in the range between
300 and 420 nm was used as the measurement of
Table 1 Clinical and biochemical characteristics of the investigated chronic kidney disease groups and controls
Group parameter PD (n=20) HD (n=20) Pre (n=36) Controls (n=26) p
Age (years) 14.3±2.3 15±3.3 14.9±3.5 14.5±3.3 NS
Gender (male/female) 12/8 10/10 17/19 12/14 NS
Dialysis vintage (months) 12±11 19±16 – – 0.02
Body mass index (kg/m2) 18.7±3.9 18.7±3.4 20.6±4.1 18.8±3.9 NS
SBP (mm Hg) 117±11a,c 128±13a,b,d 115±10a 100±9 <0.0001
DBP (mm Hg) 75±11a,c 82±10a,b,d 71±8a 64±6 <0.0001
Values are presented as the mean ± standard deviation (SD) or as a number, where appropriate
PD, peritoneal dialysis; HD, hemodialysis; Pre, predialysis group—conservative treatment; SBP, systolic blood pressure; DBP, diastolic blood pressure;
NS, non significant
a Versus control
b Versus PD
cVersus HD
dVersus Pre
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autofluorescence. The intra- and inter-day coefficient of vari-
ation for autofluorescence reader measurements was 2.7 %
(n=8) and <6 % (n=10), respectively. sAF was expressed in
arbitrary units (AU). All measurements were performed on
normal skin of the lower arm (ventral site, about 5 cm distal to
the antecubital space), without any abnormalities, at room
temperature, with the patient in a seated position.
Carotid intima-media thickness
Ultrasonographic examinations of intima-media thickness of
both common carotid arteries (cIMT) were performed using
the ALOKA ProSound SSD-5500 SV type ultrasound system
equipped with vascular 7–12 MHz probe (Hitachi Ltd., To-
kyo). All measurements were made by the same investigator,
who was blinded to the medical history of the patient being
evaluated. During the examination the child was in the supine
position with his/her head slightly tilted in the opposite direc-
tion to the area being tested. cIMT measurements were made
on the back wall of both common carotid arteries, at a height
of 1–2 cm below the bifurcation. The distance between two
distinctly shining lines of the back wall was assessed. The first
shining line represents the border between the vessel and the
inner membrane, and the second one represents the border
between the middle membrane and adventitia. The measure-
ments were repeated four times, and the mean value from all
the tests was regarded as the final result.
Statistical analysis
The results were expressed as mean values±standard devia-
tionwhen a normal distribution of variables was obtained. The
differences were then compared by analysis of variance
(ANOVA) tests. In the case of a non-normal distribution, a
non-parametric Kruskal–Wallis test for median values was
used. For evaluation of the relationship between factors,
Pearson’s correlation test was performed when a normal distri-
bution of variables was obtained, and Spearman’s test was
applied for data with a non-normal distribution. Multiple re-
gression analysis was performed with sAF as a dependent
variable. Since the p value in the ANOVA table was <0.05,
there was a statistically significant relationship between the
variables at the 95.0 % confidence level. Statistical analyses
were performed using the package STATGRAPHICS (Centu-
rion XV v.15.2.06; Statpoint Technologies, Warrenton, VA). A
p value of <0.05 was considered to be statistically significant.
Results
The clinical and biochemical characteristics of the investigat-
ed patients are described in Table 1. The groups were matched
for age, gender and BMI values. The highest values of systolic
BP (SBP) and diastolic BP were observed in children on HD,
and these were significantly different from those of children in
the PD, Pre and control groups. The mean time on PD was
shorter than that of maintenance HD duration.
Table 2 shows the results of the sAF, cIMTand endothelial
marker measurements in the examined groups with two-by-
two comparison.
sAF was significantly higher in all groups of children with
CKD than in the controls, with the highest sAF values ob-
served in the HD group. However, we were unable to dem-
onstrate a significant difference in sAF between the HD group
and the PD group. The highest values of cIMTwere observed
in children in the HD group, and these were significantly
different from the cIMT values of the other groups. cIMT
values were also increased in the PD and Pre groups as
compared to controls. All examined endothelial marker values
were highest in the HD patients. Endothelial marker values of
children in the PD and Pre groups were also significantly
increased compared to those of the controls.
Analysis of factors associated with sAF
Significantly positive linear correlations between sAF and the
mean levels of sE-selectin, MMP-9, TIMP-1, ADMA, SDMA
and PAI-1, respectively, were observed in all of the CKD
children (PD, HD and Pre groups) (Table 3). In the Pre group,
sAF level was positively correlated with sE-selectin and
ADMA levels, respectively, and negatively correlated with
creatinine clearance (p=0.0003). Detailed data are shown in
Table 3 and Fig. 1.
A multiple regression analysis of all children with CKD
revealed significantly positive associations between sAF and
sE-selectin and MMP-9 levels, respectively, as shown in
Table 4. Also in the entire CKD group, the independent
predictors of cIMTwere age, SBP and sE-selectin concentra-
tion (Table 5).
Discussion
Recent studies indicate that AGEs play a significant role in the
development of atherosclerotic lesions [21, 22]. AGEs are
classified as uremic toxins and may be formed in the course
of hyperglycemia, hyperlipidemia and oxidative and carbonyl
stress. Patients with ESKD are especially vulnerable to the
accumulation of AGEs: (1) they are at a higher risk of en-
hanced formation of AGEs “de novo” as a result of the
increased oxidative stress which accompanies uremia; (2) they
experience decreased and eventually stopped renal excretion
of these molecules’ precursors [23]. Recent research has con-
firmed that AGEs may also play a significant role in the
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pathogenesis of atherosclerosis due to their ability to induce
the inflammatory reaction by activation of RAGE [24]. In the
last decade, noninvasive examination of the levels of AGEs in
tissues based on sAF measurements has become possible. In
our study we report, for the first time, the association between
sAF and various risk factors of endothelial dysfunction and
the development of atherosclerosis in children with CKD. We
found that sAF values were elevated in all stages of the
disease. We also assessed correlations of sAF with traditional
and “new” atherosclerosis risk factors, such as the cIMT and
the concentration of markers of inflammation and/or endothe-
lial damage, including sE-selectin, MMP-9, TIMP-1, ADMA,
SDMA and PAI-1. Compared to the healthy control group,
elevated sAF values were found in all three groups of CKD
patients. As expected, the highest sAF values were observed
in children undergoing HD, although these did not differ
significantly from the values obtained in children on PD.
These results are consistent with those reported from studies
in adults [16, 25, 26]. Meerwald et al. [26] examined 109
patients treated with HD and showed that the sAF level in
these patients was twofold higher that in healthy subjects.
These authors also found that sAF intensity was an indepen-
dent predictor of increased cardiovascular mortality. In turn,
Hartog et al. [27] demonstrated, independently of other fac-
tors, the relationship of sAF with diastolic myocardial func-
tion, which is a frequently observed impairment in adult
patients with ESKD. One of the few studies in the pediatric
population focused on the concentrations of AGEs in plasma.
In this study, Sebekova and colleagues [28] evaluated the
concentrations of AGEs [fluorescent molecules and
carboxymethyllysin (CML)] in children and adolescents with
CKD, among which 18 subjects were treated conservatively,
ten remained on maintenance dialysis and nine received kid-
ney transplantation. All patients showed elevated concentra-
tions of AGEs, with the patients on dialysis having the highest
values. There was no significant correlation between the levels
of AGE in the serum and markers of inflammation [C-reactive
protein (CRP), interleukin-6, tumor necrosis factor-α]. Al-
though these results are similar to these obtained in our eval-
uation of sAF, they may not be interpreted similarly. In the
study of Sebekova and colleagues [28] there was no evidence
for a close correlation between sAF and circulating AGEs,
Table 2 Measured values of sAF, cIMT, sE-selectin, ADMA, SDMA, MMP-9, TIMP-1 and PAI-1 in patient groups and control group
Group parameter PD (n=20) HD (n=20) Pre (n=36) Controls (n=26) p
sAF (10−2 AU) 2.46±0.72a,d 2.61±0.57a,d 1.9±0.46a,b,c 1.33±0.26 <0.0001
cIMT (left carotoid artery) (mm) 0.41±0.05a,c 0.45±0.04a,b,d 0.41±0.04a,c 0.37±0.04 <0.0001
cIMT (right carotoid artery) (mm) 0.41±0.05a,c 0.44±0.04a,b,d 0.41±0.04a,c 0.36±0.03 <0.0001
sE-selectin (ng/ml) 53.34±0.49a,c,d 66.32±1.59a,b,d 46.34±0.94a,b,c 24.05±0.48 <0.0001
ADMA (μmol/l) 0.78±0.005a,c,d 0.85±0.01a,b,d 0.65±0.03a,b,c 0.39±0.008 <0.0001
SDMA (μmol/l) 0.79±0.009a,c,d 0.94±0.01a,b,d 0.69±0.02a,b,c 0.48±0.006 <0.0001
MMP-9 (ng/ml) 642±4.42a,c,d 700.7±5.29a,b,d 430±7.35a,b,c 108.9±3.35 <0.0001
TIMP-1 (ng/ml) 157.71±3.73a,c,d 415.7±28.52a,b,d 133.76±2.75a,b,c 83.13±1.67 <0.0001
PAI-1 (ng/ml) 15.83±0.28a,c,d 17.65±0.64a,b,d 11.38±0.43a,b,c 6.27±0.26 <0.0001
Values are presented as the mean ± SD
sAF, Skin autofluorescence; cIMT, Carotid intima-media thickness; ADMA, Asymmetric dimethylarginine; SDMA, symmetric dimethylarginine;
MMP-9, matrix metalloproteinase-9; TIMP-1, tissue-1 inhibitor metalloproteinases; PAI-1, plasminogen activator inhibitor type 1; AU arbitrary units
a Versus control
b Versus PD
cVersus HD
dVersus Pre
Table 3 Analyses of factors correlatedwith skin autofluorescence (10−2AU)
Variable Pearson correlation test
r p
sAF (10−2 AU) (PD + HD + Pre)
MMP-9 (ng/ml) 0.45 <0.0001
TIMP-1 (ng/ml) 0.23 0.04
sE-selectin (ng/ml) 0.46 <0.0001
ADMA (μmol/l) 0.41 <0.0001
SDMA (μmol/l) 0.37 <0.0001
PAI-1 (ng/ml) 0.46 <0.0001
sAF (10−2 AU) (Pre)
sE-selectin (ng/ml) 0.42 0.01
ADMA (μmol/l) 0.35 0.03
Creatinine clearance (ml/min/1.73 m2) −0.37 0.0003
sAF, Skin autofluorescence; cIMT, Carotid intima-media thickness;
ADMA, Asymmetric dimethylarginine; SDMA, symmetric
dimethylarginine; MMP-9, matrix metalloproteinase-9; TIMP-1, tissue-
1 inhibitor metalloproteinases; PAI-1, plasminogen activator inhibitor
type 1; AU arbitrary units; PD, peritoneal dialysis; HD, hemodialysis
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except for CML, which is only one of numerous AGEs [29].
In our study we demonstrated a positive correlation between
sAF and cIMT in the entire study population. cIMT measure-
ment is a well-known and recognized noninvasive method of
assessing the degree of severity of atherosclerotic lesions, and
the validity of this diagnostic marker has been confirmed by
many researchers, including Nishizawa et al. [30] and Tanaka
et al. [31] in adult patients treated with maintenance hemodi-
alysis. The authors of the latter study proved that in a popu-
lation of 128 dialyzed adults, cIMT, high-sensitivity CRP and
sAF were independent predictors of cardiovascular complica-
tions. In our previous study we also demonstrated a relation-
ship between sAF and the duration of dialysis and BP values,
which is consistent with the observations of Japanese re-
searchers [14, 22]. In the present study, we have shown for
the first time that in a population of children with CKD, there
is a relationship between sAF measurements and endothelial
markers such as sE-selectin, PAI-1, MMP-9, TIMP-1, ADMA
and SDMA. The significantly higher concentrations of the
latter compounds we found our pediatric patients with CKD
indicate that the stimulation and/or endothelial damage, which
is the first step in the process of atherogenesis, is already
present in the predialytic period and subsequently increases
in ESKD. Previous studies have shown conclusively that
chronic inflammation and oxidative stress play an important
role in the pathogenesis of atherosclerosis. A significant in-
volvement of sE-selectin in the process of atherogenesis was
suggested by Testa et al. [32], who demonstrated that the
Leu554Phe polymorphism of the gene encoding E-selectin
is a prerequisite for the occurrence of severe atherosclerotic
lesions. To date, few studies have shown that this mechanism
also occurs in children with CKD [33, 34]. We report here for
the first time that we found a positive correlation between sAF
measurements and sE-selectin concentration in children with
CKD. Recent studies indicate an important role of the action
of MMPs and their inhibitors in vascular remodeling in the
pathogenesis of atherosclerosis. Clinical studies have shown
that the imbalance between MMP-9 and its inhibitor TIMP-1
plays a significant role in the development of cardiovascular
pathology [35–39]. In our study we demonstrated, for the first
time, a positive correlation between sAF intensity andMMP-9
and TIMP-1 concentrations, respectively, in children with
CKD. ADMA and SDMA, as endogenous nitric oxide syn-
thase inhibitors, play an important role in the pathogenesis of
cardiovascular disease by decreasing the synthesis of nitric
oxide, which is a key vasodilator factor [40, 41]. We
Plot of Fitted Model
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Fig. 1 Correlation between
sAF and creatinine clearance
in predialysis children (r=−0.37;
p=0.0003). sAF - skin
autofluorescence (10-2 AU),
Creatinine clearance
(ml/min/1.73 m2)
Table 4 Multiple regression analysis of factors associated with skin
autofluorescence
Variable R2 β 95 % CI p
sAF (10−2 AU) (PD + HD + Pre)
MMP-9 (ng/ml) 29.6 % 0.007 −0.01-0.004 <0.0001
sE-selectin (ng/ml) 29.6 % 0.07 −0.01- 0.17 0.03
CI, Confidence interval; MMP-9, matrix metalloproteinase; AU, arbitrary
units; sAF, skin autofluorescence; PD, peritoneal dialysis; HD,
hemodialysis
Table 5 Multiple regression analysis of factors associated with carotid
intima-media thickness
Variable R2 β 95%CI p
cIMT (mm) (PD+HD+PRE)
Age (years) 33.1 % 0.006 0.003–0.01 0.006
SBP (mm Hg) 33.1 % 0.0005 −0.002 to 0.001 0.0005
sE-selectin (ng/ml) 33.1 % 0.0007 −0.0008 to 0.002 0.0007
cIMT, Carotid intima-media thickness; SBP, systolic blood pressure;
PD, peritoneal dialysis; HD, hemodialysis
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demonstrated significant correlations between sAF and
ADMA and SDMA levels. The relationship between PAI-1
overexpression and atherogenic changes has been shown in
mouse models [42] and in adults without kidney dysfunction
[43]. However, regarding the aspect of PAI-1 concentration
and cardiovascular complications, there have only been a few
studies in adults and none prior to our study in children
[44–48]. We documented a positive correlation between
PAI-1 and sAF in the entire study group of children
with CKD, as well as a positive correlation between
sAF and cIMT. In a recent study performed in children
with CKD [14], we showed significant correlations be-
tween sAF and markers of calcium and phosphate me-
tabolism abnormalities (P concentration, Ca × P index)
and hypertension; these correlations support available
data on the harmful influence of the accumulation of
AGEs in tissues in these disorders as well. It is there-
fore worth emphasizing that with the progression of
CKD in children, there is an increased accumulation of
AGEs in tissues, which was confirmed in our previous
study [14], where we showed a negative correlation
between sAF and GFR. Multivariate regression analysis
in our pediatric patient cohort with CKD showed that
the independent predictors of sAF were sE-selectin and
MMP-9 concentrations, and in the entire population,
cIMT. These results confirm that sAF may be used as
a marker of the intensity of vascular endothelial damage
of inflammatory and atherosclerotic lesions in children
with CKD.
Our study has several limitations. Firstly, the sample size,
particularly the size of the subgroups, may be insufficient to
show significant differences. Our patients were recruited from
three of the pediatric nephrology centers which treat children
from the southern region of Poland. Future studies with a
larger sample size are necessary, especially in the light of
new therapeutic methods which enable the lowering of AGEs.
Animal experiments have documented that some AGE brea-
kers may prevent alterations in vessels [49]. Lewis et al.
suggests that patients with less advanced stages of CKDmight
benefit by receiving pyridoxamine, which may inhibit the
formation of AGEs [50].
Summary
The results obtained in our study indicate a link be-
tween the accumulation of AGEs in tissues, measured as
sAF intensity, and vascular inflammatory and atheroscle-
rotic changes in children and young adults with CKD.
We therefore suggest that sAF may be, in the future, a
useful tool for risk stratification in this group of patients
and an easy and repeatable method for monitoring the
effects of therapy. Further studies are needed to clarify
whether the accumulation of AGEs in tissues could be a
new therapeutic target for improving cardiovascular
complications in the CKD population.
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